263 related articles for article (PubMed ID: 30790690)
1. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
[TBL] [Abstract][Full Text] [Related]
2. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
[TBL] [Abstract][Full Text] [Related]
3. Current status of data on cangrelor.
Qamar A; Bhatt DL
Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
[TBL] [Abstract][Full Text] [Related]
5. Periprocedural platelet inhibition with cangrelor in P2Y
Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
[TBL] [Abstract][Full Text] [Related]
6. Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
Yerasi C; Case BC; Chezar-Azerrad C; Forrestal BJ; Medranda GA; Shea C; Zhang C; Ben-Dor I; Satler LF; Bernardo NL; Hashim H; Garcia-Garcia HM; Waksman R
Am Heart J; 2021 Aug; 238():59-65. PubMed ID: 33961829
[TBL] [Abstract][Full Text] [Related]
7. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention.
Hideo-Kajita A; Rogers T; Buchanan K; Iantorno M; Gajanana D; Ozaki Y; Dan K; Kolm P; Brathwaite E; Beyene S; Melaku G; Meirovich Y; Dheendsa A; Garcia-Garcia HM; Torguson R; Waksman R
Am J Cardiol; 2019 Apr; 123(8):1228-1238. PubMed ID: 30738570
[TBL] [Abstract][Full Text] [Related]
8. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Franchi F; Rollini F; Park Y; Angiolillo DJ
Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
[TBL] [Abstract][Full Text] [Related]
10. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
11. GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation.
Kanic V; Vollrath M; Penko M; Markota A; Kompara G; Kanic Z
Heart Lung Circ; 2018 Jan; 27(1):73-78. PubMed ID: 28377230
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and safety of cangrelor in patients with suboptimal P2Y
Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
14. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the Use of Cangrelor in the Real World.
Qamar A; Bhatt DL
Am J Cardiovasc Drugs; 2017 Feb; 17(1):5-16. PubMed ID: 27677505
[TBL] [Abstract][Full Text] [Related]
16. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
Capodanno D; Milluzzo RP; Angiolillo DJ
Ther Adv Cardiovasc Dis; 2019; 13():1753944719893274. PubMed ID: 31823688
[TBL] [Abstract][Full Text] [Related]
17. Cangrelor for treatment during percutaneous coronary intervention.
Oestreich JH; Dobesh PP
Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
[TBL] [Abstract][Full Text] [Related]
18. What is the Role of Cangrelor in Patients Undergoing PCI?
Droppa M; Geisler T
Curr Vasc Pharmacol; 2018; 16(5):484-489. PubMed ID: 29345586
[TBL] [Abstract][Full Text] [Related]
19. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
Majmundar M; Kansara T; Jain A; Shah P; Mithawala P; Desai R; Shah P; Doshi R
Am J Cardiol; 2019 Apr; 123(7):1069-1075. PubMed ID: 30654930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
